Hassan Taha, MD
Pulmonary Disease · Topeka, KSNPI 1396051595
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (56.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 72.8% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $6,628, more than ten times the $370 reported in 2019.
Across 40 payments — averaging $177.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Pulmonx Corporation$1K
- GSK$121
- Boehringer Ingelheim$90
- Mylan Specialty L.p.$56
- Insmed, Inc.$50
- plus $160 from 6 others
What the payments were for
- Travel & lodging$2,31633%
- Food & beverage$79011%
- Education$4,00056%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $5,176 |
| Pulmonx Corporation | 3 | $1,453 |
| GSK | 7 | $121 |
| Boehringer Ingelheim | 4 | $90 |
| Mylan Specialty L.p. | 4 | $56 |
| Insmed, Inc. | 3 | $50 |
| AstraZeneca | 3 | $45 |
| Genentech USA, Inc. | 3 | $45 |
| Actelion Pharmaceuticals US, Inc. | 3 | $43 |
| Shire North American Group Inc | 1 | $12 |
| Electromed, Inc. | 1 | $11 |
| Veran Medical Technologies, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,106 in reported general payments places this provider in the 75th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 11 | $141,765 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 170 | $137,017 |
| Spiriva RespimatTiotropium Bromide | 91 | $62,518 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 107 | $52,541 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 63 | $51,473 |
| Ambrisentan | 12 | $33,991 |
| Advair HfaFluticasone Propion/Salmeterol | 45 | $29,287 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 26 | $26,557 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $22,457 |
| Incruse ElliptaUmeclidinium Bromide | 57 | $20,601 |
| Spiriva HandihalerTiotropium Bromide | 29 | $15,612 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $12,458 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 112 | $12,008 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 84 | $11,330 |
| Sildenafil Citrate | 14 | $10,693 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $121 | $242,305429 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $43 | $141,76511 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $90 | $98,910135 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Pulmicort Flexhaler | $45 | $75,557146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Topeka
- Miguel Tsukayama OdaTopeka$6K
- Vimalkumar PatelTopeka$5K
- Abhishek ChakrabortiTopeka$4K
- Amanda GudgellTopeka$856
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
- Chase HallKansas City$329K
- Maykol Postigo JasahuiKansas City$322K
- Abdel-Ghanie Abu-SamraWichita$60K
- Robert SourkHutchinson$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.